TY - JOUR
T1 - Personalized early detection and prevention of breast cancer
T2 - ENVISION consensus statement
AU - Pashayan, Nora
AU - Antoniou, Antonis C.
AU - Ivanus, Urska
AU - Esserman, Laura J.
AU - Easton, Douglas F.
AU - French, David
AU - Sroczynski, Gaby
AU - Hall, Per
AU - Cuzick, Jack
AU - Evans, D. Gareth
AU - Simard, Jacques
AU - Garcia-Closas, Montserrat
AU - Schmutzler, Rita
AU - Wegwarth, Odette
AU - Pharoah, Paul
AU - Moorthie, Sowmiya
AU - De Montgolfier, Sandrine
AU - Baron, Camille
AU - Herceg, Zdenko
AU - Turnbull, Clare
AU - Balleyguier, Corinne
AU - Rossi, Paolo Giorgi
AU - Wesseling, Jelle
AU - Ritchie, David
AU - Tischkowitz, Marc
AU - Broeders, Mireille
AU - Reisel, Dan
AU - Metspalu, Andres
AU - Callender, Thomas
AU - de Koning, Harry
AU - Devilee, Peter
AU - Delaloge, Suzette
AU - Schmidt, Marjanka K.
AU - Widschwendter, Martin
N1 - Publisher Copyright:
© 2020, The Author(s).
PY - 2020/11/1
Y1 - 2020/11/1
N2 - The European Collaborative on Personalized Early Detection and Prevention of Breast Cancer (ENVISION) brings together several international research consortia working on different aspects of the personalized early detection and prevention of breast cancer. In a consensus conference held in 2019, the members of this network identified research areas requiring development to enable evidence-based personalized interventions that might improve the benefits and reduce the harms of existing breast cancer screening and prevention programmes. The priority areas identified were: 1) breast cancer subtype-specific risk assessment tools applicable to women of all ancestries; 2) intermediate surrogate markers of response to preventive measures; 3) novel non-surgical preventive measures to reduce the incidence of breast cancer of poor prognosis; and 4) hybrid effectiveness–implementation research combined with modelling studies to evaluate the long-term population outcomes of risk-based early detection strategies. The implementation of such programmes would require health-care systems to be open to learning and adapting, the engagement of a diverse range of stakeholders and tailoring to societal norms and values, while also addressing the ethical and legal issues. In this Consensus Statement, we discuss the current state of breast cancer risk prediction, risk-stratified prevention and early detection strategies, and their implementation. Throughout, we highlight priorities for advancing each of these areas.
AB - The European Collaborative on Personalized Early Detection and Prevention of Breast Cancer (ENVISION) brings together several international research consortia working on different aspects of the personalized early detection and prevention of breast cancer. In a consensus conference held in 2019, the members of this network identified research areas requiring development to enable evidence-based personalized interventions that might improve the benefits and reduce the harms of existing breast cancer screening and prevention programmes. The priority areas identified were: 1) breast cancer subtype-specific risk assessment tools applicable to women of all ancestries; 2) intermediate surrogate markers of response to preventive measures; 3) novel non-surgical preventive measures to reduce the incidence of breast cancer of poor prognosis; and 4) hybrid effectiveness–implementation research combined with modelling studies to evaluate the long-term population outcomes of risk-based early detection strategies. The implementation of such programmes would require health-care systems to be open to learning and adapting, the engagement of a diverse range of stakeholders and tailoring to societal norms and values, while also addressing the ethical and legal issues. In this Consensus Statement, we discuss the current state of breast cancer risk prediction, risk-stratified prevention and early detection strategies, and their implementation. Throughout, we highlight priorities for advancing each of these areas.
UR - http://www.scopus.com/inward/record.url?scp=85086563806&partnerID=8YFLogxK
U2 - 10.1038/s41571-020-0388-9
DO - 10.1038/s41571-020-0388-9
M3 - Review article
C2 - 32555420
AN - SCOPUS:85086563806
SN - 1759-4774
VL - 17
SP - 687
EP - 705
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
IS - 11
ER -